Fibroblast Growth Factor 23–Induced Hypophosphatemia in Acute Leukemia
نویسندگان
چکیده
منابع مشابه
Fibroblast Growth Factor 23 and Hypophosphatemia: A Case of Hypophosphatemia along the Rickets-Osteomalacia Spectrum.
Phosphorus is a key component of bone, and a deficiency results in poor mineralization along with other systemic symptoms of hypophosphatemia. Various causes of hypophosphatemia with renal wasting of phosphorus have been identified. These include the Fanconi syndrome, various genetic mutations of fibroblast growth factor 23 (FGF23) handling and the sodium/phosphate cotransporter, and those due ...
متن کاملFibroblast Growth Factor-1 vs. Fibroblast Growth Factor-2 in Ischemic Skin Flap Survival in a Rat Animal Model
BACKGROUND One of the main challenges in skin flap surgery is tissue ischemia and following necrosis. The present study compares the effects of fibroblast growth factors 1 and 2 on increasing cutaneous vasculature, improving ischemia, and preventing distal necrosis in ischemic skin flaps in rat model. METHODS Thirty rats were allocated into 3 groups (n=10) and 2×8 cm dorsal rando...
متن کاملExpression of fibroblast growth factor receptors in human leukemia cells.
We have previously cloned from K562 leukemia cells two novel fibroblast growth factor receptors (FGFR-3 and FGFR-4; J. Partanen et al., EMBO J., 10: 1347-1354, 1991). Here we have analyzed the mRNA expression of four different FGFRs, including the two novel genes in human leukemia cell lines. We show FGFR-1, FGFR-3, and FGFR-4 mRNAs in several leukemia cell lines at levels similar to those in s...
متن کاملOverexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia.
Basic fibroblast growth factor (bFGF) is known to play a critical role in tumorigenesis of solid tumors. The importance of bFGF in hematological malignancies such as acute myeloid leukemia (AML) remains to be elucidated. Therefore, we determined bFGF protein expression by immunohistochemical analyses in bone marrow biopsies of patients with newly diagnosed, untreated AML. The expression of bFGF...
متن کاملSorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.
Sorafenib, a drug approved for the treatment of advanced renal cancer, inhibits RAF/MAPK pathway, vascular endothelial receptor-2 and -3, platelet-derived growth factor receptor-2 and -3, and c-Kit [1]. Hypophosphatemia is a common side-effect, occurring in 45% of patients [2]. This metabolic derangement is mostly asymptomatic, but the mechanisms involved are unclear [2]. The physiological bala...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Endocrine Society
سال: 2018
ISSN: 2472-1972
DOI: 10.1210/js.2018-00010